Cancer/Tumor Profiling Market

Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025

Report Code: MD 4803 Jul, 2020, by marketsandmarkets.com

[302 Pages Report] The global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9% during the forecast period. The increasing incidence of cancer across the globe and the growing use of biomarkers in tumor profiling are the primary growth drivers for this market. In addition, the increase in cancer research and funding initiatives and technological advancements in profiling technologies are also propelling the growth of the cancer/tumor profiling market.

Also, the increasing demand for personalized medicine and the growing need for point-of-care diagnostics is expected to offer significant growth opportunities for market players during the forecast period. On the other hand, the high capital investment required for biomarker discovery and the technical issues with sample collection and storage are the key factors restraining market growth to a certain extent.

Cancer/Tumor Profiling Market

Impact of Covid-19 on the cancer/tumor profiling market in the forecast period (2020-2025)

The cancer/tumor profiling market is not expected to be significantly impacted by the COVID-19 pandemic in 2020-2021. Due to the COVID-19 outbreak, there has been a significant drop in cancer testing and diagnosis due to measures and resources implemented towards coronavirus. However, several patients affected with COVID-19 were people with malignancies, due to which cancer has been identified as a risk factor for COVID-19. Research in this area is further undertaken to understand the dynamics of the infection better, which is expected to propel the cancer research field further. On the other hand, we are estimating that the major share of tumor diagnostic and prognostic testing of cancer, along with personalized medicine, will grow at a stable pace in the next five years. There is a huge deferment of treatment schedule of surgeries, radiation therapy, and chemotherapy sessions. Hence, the cancer treatment of surgeries, radiation therapy, and chemotherapy sessions should come to the levels of 2019 by the first quarter of 2021.

Drivers, Restraints, Opportunities, and Challenges in the Cancer/Tumor Profiling Market (2020-2025)

Driver: Increasing incidence of cancer

Rise in cancer incidences is one of the major contributors to market growth in the overall cancer/tumor profiling market. The increasing burden of cancer can be attributed to several factors, including population growth and aging, as well as the changing prevalence of certain causes of cancer linked to social and economic development.

Restraint: Technical issues in sample collection and storage in the cancer/tumor profiling market

Sample collection is one of the key issues faced by service providers, followed by access to these samples. Stringent quality control of these samples is required, and they need to be stored under the right conditions to avoid any loss.

Opportunity: Increasing demand for personalized medicine

Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing the way many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology.

Challenge: Poor regulatory and reimbursement scenario

Technological advancements have enhanced the development and use of tumor profiling technologies to identify the key attributes of a patient’s disease at an early stage and thus guide the selection of the therapy to benefit a particular patient. The acceptance of biomarker-based tests in clinical applications requires evidence of the biomarker’s clinical validity and utility. This is important not just only to help physicians in the decision-making process but also to achieve regulatory approvals and reimbursements for tests. However, amassing the data necessary to show clinical validity and utility may be a time-consuming and expensive process, which is further complicated by the lack of standard regulations.

Cancer/Tumor Profiling Market Interconnections

The immunoassays segment is expected to account for the largest share of the market, by technology, in 2019

Based on technology, the cancer/tumor profiling market has been segmented into immunoassays, in situ hybridization, next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and other technologies. The immunoassays segment accounted for the largest market share in 2019. These assays are used as a gold standard to conduct tumor profiling on a large scale as they help measure the presence and concentration of analytes in a sample. These tests are used for cancer diagnosis, prognosis, and treatment decisions. Moreover, the information gained by these tests in clinical settings helps shorten hospital stays and decrease the severity of illnesses by identifying and assessing the progression of the disease, leading to improved therapeutic choices.

The lung cancer segment is expected to grow at the highest CAGR during the forecast period

Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers. In 2019, the breast cancer segment accounted for the largest share of the cancer/tumor profiling market, followed by lung cancer. The high prevalence of breast cancer across the globe is the major factor contributing to the large share of this segment. However, the lung cancer segment is expected to register the highest during the forecast period. The increasing incidence of lung cancer worldwide and the rising need for early diagnosis are supporting the growth of this segment.

The protein biomarker segment is expected to grow at the highest CAGR during the forecast period

Based on biomarker type, the cancer/tumor profiling market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers. In 2019, the genetic biomarkers segment accounted for the largest share of the cancer/tumor profiling market. The large share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process. On the other hand, the protein biomarkers segment is estimated to grow at the highest CAGR during the forecast period majorly due to the increasing adoption of proteomic methods for biomarker research to improve the drug development process. They also showcase the enormous potential for directing personalized cancer therapy and treatment monitoring.

Research to account for the largest share of the market, by application, in 2019

Based on applications, the cancer/tumor profiling market is segmented into research and clinical applications. The research applications segment accounted for the largest share of the cancer/tumor profiling market in 2019. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.

Cancer/Tumor Profiling Market By Region

The APAC market is expected to grow at the highest CAGR during the forecast period

The cancer/tumor profiling market in the Asia Pacific is expected to witness the highest CAGR during the forecast period. Factors such as the high incidence of cancer, growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics are expected to drive the growth of this market during the forecast period.

Key Market Players

The prominent players in the Cancer/Tumor Profiling Market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium).

Illumina is a molecular diagnostics company engaged in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variations and biological functions. The company offers a wide range of integrated sequencing and microarray systems, consumables, and analysis tools to accelerate and simplify genetic analysis. The company operates under two units—Product Revenue and Services & Other Revenue. The Product Revenue unit consists of consumables and instruments revenue, while the Services and Other Revenue unit consists of sequencing, genotyping, and instrument service contract revenue.

Scope of the Report:

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Technology, Cancer Type, Biomarker Type, Application and Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

Companies covered

Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Diagnostics (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq(US), Histogene X (Belgium).
 

The research report categorizes the market into the following segments and subsegments:

Cancer/Tumor Profiling Market, by Technology

  • COVID Impact on the Market, By Technology
  • Immunoassays
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Mass Spectrometry
  • In-Situ Hybridization
  • Microarrays
  • Others 

Cancer/Tumor Profiling Market, by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Other Cancer 

Cancer/Tumor Profiling Market by Biomarker Type

  • Genomic Biomarker
  • Protein Biomarker 

Cancer/Tumor Profiling Market by Application

  • COVID Impact on the Market
  • Research
  • Biomarker Discovery
  • Personalized Medicine
  • Clinical Application
  • Diagnostics
  • Prognostics
  • Screening
  • Treatment & Monitoring 

Cancer/Tumor Profiling Market, by Region

  • COVID Impact on the Market
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
  • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In 2020, Illumina’s COVID response: Illumina partnered with IDbyDNA Partner to deliver NGS Infectious Disease solutions. The partnership aims to accelerate NGS’ adoption of clinical infectious disease testing. This partnership also aims to make next-generation software with powerful bioinformatics software that can turn data into actionable insights.
  • In 2018, Illumina acquired Edico Genome, a leading provider of data analysis acceleration solutions for NGS, to accelerate genomic data analysis.
  • In 2018, Illumina signed an agreement to acquire Pacific Biosciences to integrate Pacific’s sequencing solutions into the company and expand its offering of integrated workflows.
  • In 2017, Illumina opened its Solutions Center in the Genopole Campus in France as a customer-training center to support the development of skills for the expanding genomics industry in the country.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 36)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION & SCOPE
           1.2.1 MARKETS COVERED
                 FIGURE 1 CANCER/TUMOR PROFILING MARKET
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 STAKEHOLDERS
    1.5 LIMITATIONS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 40)
    2.1 RESEARCH APPROACH
        FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Breakdown of primaries
                            FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.1.2.3 Key industry insights
    2.2 MARKET SIZING & VALIDATION APPROACH
        FIGURE 4 SEGMENTAL SHARE ANALYSIS ILLUSTRATION
        FIGURE 5 TOP-DOWN APPROACH
    2.3 DATA TRIANGULATION APPROACH
        FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 49)
  FIGURE 7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
  FIGURE 8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020 VS. 2025 (USD MILLION)
  FIGURE 9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020 VS. 2025 (USD MILLION)
  FIGURE 10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
  FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
        FIGURE 12 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
    4.2 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
        FIGURE 13 CHINA TO REGISTER THE FASTEST GROWTH IN THE CANCER/ TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
    4.3 REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2020-2025)
        FIGURE 14 APAC TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD (2020-2025)
    4.4 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2020 VS. 2025)
        FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2020 & 2025

5 MARKET OVERVIEW (Page No. - 58)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 16 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Increasing incidence of cancer
                            FIGURE 17 GLOBAL CANCER INCIDENCE, 2008-2030
                    5.2.1.2 Increasing use of biomarkers in cancer profiling
                    5.2.1.3 Increasing cancer research and funding
                    5.2.1.4 Technological advancements
                            TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 High capital investment
                    5.2.2.2 Technical issues with sample collection and storage
                            TABLE 2 MARKET RESTRAINTS: IMPACT ANALYSIS
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Increasing demand for personalized medicine
                            FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016
                    5.2.3.2 Growing need for point-of-care diagnostics
                            TABLE 3 MARKET OPPORTUNITIES: IMPACT ANALYSIS
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Low biomarker discovery-to-approval ratio
                    5.2.4.2 Poor regulatory and reimbursement scenario
                            TABLE 4 MARKET CHALLENGES: IMPACT ANALYSIS
 
6 INDUSTRY INSIGHTS (Page No. - 67)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
        FIGURE 19 INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS
           6.2.1 INTEGRATION OF OMICS DATA
           6.2.2 ADVANCES IN LIQUID BIOPSY
           6.2.3 ORGANOIDS FOR PERSONALIZED MEDICINE
    6.3 COVID-19 IMPACT ON THE CANCER/TUMOR PROFILING MARKET
        FIGURE 20 IMPACT OF COVID-19 ON THE CANCER/TUMOR PROFILING MARKET

7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (Page No. - 71)
    7.1 INTRODUCTION
    7.2 COVID-19 IMPACT, BY TECHNOLOGY
        FIGURE 21 IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
        TABLE 5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
        TABLE 6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    7.3 IMMUNOASSAYS
           7.3.1 IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
                 TABLE 7 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 8 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    7.4 NEXT GENERATION SEQUENCING
           7.4.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
                 TABLE 9 CANCER/TUMOR PROFILING MARKET FOR NEXT GENERATION SEQUENCING, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 10 CANCER/TUMOR PROFILING MARKET FOR NEXT GENERATION SEQUENCING, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    7.5 POLYMERASE CHAIN REACTION
           7.5.1 REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
                 TABLE 11 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 12 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    7.6 IN SITU HYBRIDIZATION
           7.6.1 FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
                 TABLE 13 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 14 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    7.7 MICROARRAYS
           7.7.1 MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
                 TABLE 15 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 16 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    7.8 MASS SPECTROMETRY
           7.8.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS
                 TABLE 17 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    7.9 OTHER TECHNOLOGIES
        TABLE 19 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
        TABLE 20 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE (Page No. - 90)
    8.1 INTRODUCTION
        FIGURE 22 BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
        TABLE 21 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
        TABLE 22 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    8.2 BREAST CANCER
           8.2.1 BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
                 TABLE 23 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 24 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    8.3 LUNG CANCER
           8.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
                 FIGURE 23 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
                 TABLE 25 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 26 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    8.4 COLORECTAL CANCER
           8.4.1 IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
                 FIGURE 24 COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018)
                 TABLE 27 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 28 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    8.5 PROSTATE CANCER
           8.5.1 PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
                 TABLE 29 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 30 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    8.6 MELANOMA
           8.6.1 RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
                 TABLE 31 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 32 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    8.7 OTHER CANCERS
        TABLE 33 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
        TABLE 34 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE (Page No. - 107)
    9.1 INTRODUCTION
        FIGURE 25 GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
        TABLE 35 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
        TABLE 36 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    9.2 GENETIC BIOMARKERS
           9.2.1 GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
                 TABLE 37 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 38 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    9.3 PROTEIN BIOMARKERS
           9.3.1 PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
                 TABLE 39 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                 TABLE 40 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    9.4 OTHER BIOMARKERS
        TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
        TABLE 42 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION (Page No. - 116)
     10.1 INTRODUCTION
     10.2 COVID-19 IMPACT, BY APPLICATION
          FIGURE 26 RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
          TABLE 43 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2017-2019 (USD MILLION)
          TABLE 44 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2020-2025 (USD MILLION)
     10.3 RESEARCH APPLICATIONS
          TABLE 45 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 46 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             10.3.1 BIOMARKER DISCOVERY
                       10.3.1.1 Biomarkers are being exploited for the development of personalized or precision medicine
                                TABLE 47 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                                TABLE 48 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
             10.3.2 PERSONALIZED MEDICINE
                       10.3.2.1 The field of personalized medicine is witnessing rapid growth in the area of oncology
                                TABLE 49 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                                TABLE 50 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
     10.4 CLINICAL APPLICATIONS
          TABLE 51 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 52 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             10.4.1 DIAGNOSTICS
                       10.4.1.1 Tumor profiling is rapidly gaining momentum in the area of diagnostics
                                TABLE 53 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                                TABLE 54 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
             10.4.2 PROGNOSTICS
                       10.4.2.1 Advancements in molecular biology are aiding the uptake of tumor profiling in this segment
                                TABLE 55 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                                TABLE 56 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
             10.4.3 MONITORING & TREATMENT
                       10.4.3.1 Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients
                                TABLE 57 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                                TABLE 58 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
             10.4.4 SCREENING
                       10.4.4.1 Screening tests help in deciding if diagnostic tests are required by the patient
                                TABLE 59 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
                                TABLE 60 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

11 CANCER/TUMOR PROFILING MARKET, BY REGION (Page No. - 133)
     11.1 INTRODUCTION
     11.2 COVID-19 IMPACT, BY REGION
          FIGURE 27 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT
          TABLE 61 CANCER/TUMOR PROFILING MARKET, BY REGION, 2017-2019 (USD MILLION)
          TABLE 62 CANCER/TUMOR PROFILING MARKET, BY REGION, 2020-2025 (USD MILLION)
     11.3 NORTH AMERICA
          FIGURE 28 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
          TABLE 63 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
          TABLE 64 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
          TABLE 65 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
          TABLE 66 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
          TABLE 67 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
          TABLE 68 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
          TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
          TABLE 70 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
          TABLE 71 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 72 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
          TABLE 73 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 74 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.3.1 US
                       11.3.1.1 US dominates the North American cancer/tumor profiling market
                                TABLE 75 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 76 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 77 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 78 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 79 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 80 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 81 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 82 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 83 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 84 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.3.2 CANADA
                       11.3.2.1 Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada
                                TABLE 85 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 86 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 87 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 88 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 89 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 90 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 91 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 92 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 93 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 94 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
     11.4 EUROPE
          FIGURE 29 EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT
          TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
          TABLE 96 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
          TABLE 97 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
          TABLE 98 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,2020-2025 (USD MILLION)
          TABLE 99 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
          TABLE 100 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
          TABLE 101 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
          TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
          TABLE 103 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 104 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
          TABLE 105 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 106 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.4.1 GERMANY
                       11.4.1.1 Advancements in proteomics and genomics research are expected to drive market growth
                                TABLE 107 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 108 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 109 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 110 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 111 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 112 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 113 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 114 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 115 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 116 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.4.2 UK
                       11.4.2.1 Growth in the life sciences industry and the increase in academia-industry partnerships will be the key factors driving the market
                                TABLE 117 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 118 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 119 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 120 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 121 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 122 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 123 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 124 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 125 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 126 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.4.3 FRANCE
                       11.4.3.1 Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development
                                TABLE 127 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 128 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 129 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 130 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 131 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 132 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 133 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 134 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 135 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 136 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.4.4 ITALY
                       11.4.4.1 Increasing investment in cancer and translational research is expected to propel market growth during the forecast period
                                TABLE 137 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 138 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 139 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 140 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 141 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 142 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 143 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 144 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 145 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 146 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.4.5 SPAIN
                       11.4.5.1 Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain
                                TABLE 147 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 148 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 149 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 150 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 151 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 152 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 153 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 154 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 155 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 156 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.4.6 REST OF EUROPE
                    TABLE 157 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                    TABLE 158 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                    TABLE 159 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                    TABLE 160 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                    TABLE 161 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                    TABLE 162 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                    TABLE 163 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 164 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                    TABLE 165 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 166 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
     11.5 ASIA PACIFIC
          FIGURE 30 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
          TABLE 167 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,2017-2019 (USD MILLION)
          TABLE 168 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
          TABLE 169 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
          TABLE 170 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
          TABLE 171 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
          TABLE 172 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
          TABLE 173 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
          TABLE 174 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
          TABLE 175 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 176 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
          TABLE 177 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
          TABLE 178 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.5.1 JAPAN
                       11.5.1.1 Large number of research initiatives towards the development of precision medicine supporting market growth in Japan
                                TABLE 179 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 180 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 181 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 182 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 183 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 184 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 185 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 186 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 187 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 188 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.5.2 CHINA
                       11.5.2.1 China has the fastest-growing research sector in the APAC region
                                TABLE 189 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 190 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 191 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 192 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 193 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 194 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 195 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 196 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 197 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 198 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.5.3 INDIA
                       11.5.3.1 Increasing pharma R&D and government funding in the biotechnology industry are the major factors driving market growth in India
                                TABLE 199 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                                TABLE 200 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                                TABLE 201 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                                TABLE 202 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                                TABLE 203 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                                TABLE 204 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                                TABLE 205 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 206 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                                TABLE 207 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                                TABLE 208 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
             11.5.4 REST OF ASIA PACIFIC
                    TABLE 209 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                    TABLE 210 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                    TABLE 211 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                    TABLE 212 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                    TABLE 213 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                    TABLE 214 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                    TABLE 215 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 216 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                    TABLE 217 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 218 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
     11.6 LATIN AMERICA
             11.6.1 GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH
                    TABLE 219 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                    TABLE 220 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                    TABLE 221 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                    TABLE 222 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                    TABLE 223 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                    TABLE 224 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                    TABLE 225 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 226 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                    TABLE 227 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 228 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
     11.7 MIDDLE EAST & AFRICA
             11.7.1 GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH
                    TABLE 229 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
                    TABLE 230 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
                    TABLE 231 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
                    TABLE 232 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
                    TABLE 233 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
                    TABLE 234 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
                    TABLE 235 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 236 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
                    TABLE 237 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
                    TABLE 238 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 224)
     12.1 OVERVIEW
          FIGURE 31 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2016 TO APRIL 2020
     12.2 COMPETITIVE LEADERSHIP MAPPING
             12.2.1 VISIONARY LEADERS
             12.2.2 INNOVATORS
             12.2.3 DYNAMIC DIFFERENTIATORS
             12.2.4 EMERGING COMPANIES
                    FIGURE 32 CANCER/TUMOR PROFILING MARKET: COMPETITIVE LEADERSHIP MAPPING (2018)
     12.3 COMPETITIVE SITUATION AND TRENDS
             12.3.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
                    TABLE 239 PRODUCT LAUNCHES, 2016-2020
             12.3.2 EXPANSIONS
                    TABLE 240 EXPANSIONS, 2016-2020
             12.3.3 ACQUISITIONS
                    TABLE 241 ACQUISITIONS, 2016-2020
             12.3.4 OTHER STRATEGIES
                    TABLE 242 OTHER STRATEGIES, 2016-2020

13 COMPANY PROFILES (Page No. - 231)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
     13.1 ILLUMINA, INC.
          FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2019)
     13.2 QIAGEN N.V.
          FIGURE 34 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
     13.3 NEOGENOMICS, INC.
          FIGURE 35 NEOGENOMICS, INC.: COMPANY SNAPSHOT (2019)
     13.4 SYSMEX CORPORATION
          FIGURE 36 SYSMEX CORPORATION: COMPANY SNAPSHOT (2019)
     13.5 HTG MOLECULAR DIAGNOSTICS, INC.
          FIGURE 37 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2019)
     13.6 HELOMICS CORPORATION
     13.7 CARIS LIFE SCIENCES
     13.8 NANOSTRING TECHNOLOGIES, INC.
          FIGURE 38 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
     13.9 RIBOMED BIOTECHNOLOGIES, INC.
     13.1 GUARDANT HEALTH, INC.
          FIGURE 39 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2019)
      13.11 FOUNDATION MEDICINE
      13.12 F. HOFFMANN-LA ROCHE LTD
            FIGURE 40 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)
      13.13 GENSCRIPT BIOTECH CORPORATION
            FIGURE 41 GENSCRIPT: COMPANY SNAPSHOT (2019)
      13.14 TEMPUS LABS
      13.15 HISTOGENE X
      13.16 OTHER COMPANIES
              13.16.1 HOLOGIC, INC.
              13.16.2 BOREAL GENOMICS INC
              13.16.3 PERTHERA
              13.16.4 AGENDIA
              13.16.5 OMNISEQ
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 293)
     14.1 INSIGHTS OF INDUSTRY EXPERTS
     14.2 DISCUSSION GUIDE
     14.3 DKNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
     14.4 AVAILABLE CUSTOMIZATIONS
     14.5 RELATED REPORTS
     14.6 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of widespread secondary sources; directories; databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of global cancer/tumor profiling market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, key developments related to market, and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in cancer/tumor profiling market. The primary sources from the demand side include industry experts such as surgeons, physicians and doctors, and life science researchers.

A breakdown of the primary respondents is provided below:

Cancer/Tumor Profiling Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by technology, by cancer type, by biomarker type, application, and region).

Data Triangulation

After arriving at the market size, cancer/tumor profiling market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, segment, and forecast cancer/tumor profiling market by product, indication, application, end user, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to overall cancer/tumor profiling market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of cancer/tumor profiling market in five main regions along with their respective key countries, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players in cancer/tumor profiling market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as acquisitions; new product launches; expansions; collaborations, agreements, and partnerships; and R&D activities of the leading players in cancer/tumor profiling market
  • To benchmark players within cancer/tumor profiling market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)

Geographic Analysis

  • A further breakdown of the Latin American cancer/tumor profiling market into Brazil, Mexico, and the Rest of Latin America
  • A further breakdown of European cancer/tumor profiling market into Switzerland, Netherlands, and the Rest of Europe.
COVID-19

Get in-depth analysis of the COVID-19 impact on the Cancer/Tumor Profiling Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Cancer/Tumor Profiling Market

Request For Special Pricing
Report Code
MD 4803
Published ON
Jul, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cancer/Tumor Profiling Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home